FIP: Understanding Feline Infectious Peritonitis and the New Treatment Options

FIP: A Disease That Has Changed Dramatically

Feline infectious peritonitis (FIP) was, until very recently, almost universally fatal. The disease — caused by a mutated form of feline enteric coronavirus (FCoV) that escapes macrophage-mediated immune defense and causes progressive systemic disease — killed the vast majority of cats diagnosed with it within weeks to months. The development and approval of antiviral treatments has fundamentally changed this picture, making FIP a survivable disease for many cats when diagnosed and treated promptly. Understanding FIP is more important than ever because of this treatment shift.

What FIP Is and How It Develops

FCoV is an extremely common coronavirus that infects the gastrointestinal tract of cats; most infections are mild or subclinical. In a small percentage of infected cats — estimated 1-5% — the virus mutates and gains the ability to infect and replicate within macrophages (immune cells), causing FIP. Why this mutation occurs in some cats and not others is multifactorial and not fully understood; genetic susceptibility, viral load, and immune status all play roles. FIP is more common in cats under 2 years and over 10 years, in purebred cats, and in multi-cat environments where FCoV circulation is higher.

Forms of FIP

FIP has two main presentations. Wet (effusive) FIP: protein-rich fluid accumulates in the abdomen and/or chest cavity, causing visible distension or difficulty breathing. This form typically progresses more rapidly. Dry (non-effusive) FIP: granulomas form in organs without significant fluid; signs depend on which organs are affected (eyes, brain, kidneys, liver). Neurological FIP and ocular FIP (often causing uveitis) are subforms of dry FIP. Some cats have a mixed presentation.

Antiviral Treatment

GS-441524 (a nucleoside analog) and remdesivir (its prodrug) have transformed FIP outcomes. In multiple studies and large-scale compassionate use, cats treated with these antivirals achieve sustained remission (no recurrence after stopping treatment) in approximately 80-90% of cases when diagnosed early. Treatment is typically 12 weeks of daily medication. As of recent years, GS-441524-based products have become available through licensed veterinary distributors and compounding pharmacies with prescriptions. Diagnosis requires compatible clinical signs, laboratory findings (high total protein, low albumin-to-globulin ratio, elevated alpha-1 glycoprotein), and ideally PCR confirmation.